SOURCE: Galea Life Sciences, Inc.

Galea Life Sciences, Inc.

June 08, 2009 10:35 ET

Galea Life Sciences, Inc. Announces Completion of 2008 Audit

ORLANDO, FL--(Marketwire - June 8, 2009) - Galea Life Sciences, Inc., maker of Nutraplete™ therapeutic drink mix and a pioneer in the field of therapeutic nutrition, announces the completion of its financial audit for its fiscal year ended October 31, 2008. The Company intends to file a new Form 10 registration statement with the SEC. The Company expects its Common stock to open trading on the Over The Counter Bulletin Board (OTCBB), if and when it clears SEC comments on the Form 10, and FINRA has accepted the Company's stock for quotation.

About Nutraplete™

Nutraplete Therapeutic Drink Mix is the first therapeutic nutritional dietary supplement created specifically to help people living with HIV/AIDS. This multi-nutritional, therapeutic "functional food" includes pharmaceutical grade supplements that may provide health benefits by addressing common nutritional deficiencies. Nutraplete is available by prescription and currently approved for Medicaid reimbursement in New York State, New Jersey, Connecticut, Illinois, Nevada and Washington State. The company is currently seeking Medicaid approval in California, Florida, Pennsylvania, Maryland, Washington, D.C. and other states. For more information:

Nutraplete is distributed exclusively in the U.S. by Allion Healthcare, Inc. ( (NASDAQ: ALLI) under its MOMS Pharmacy trade name. MOMS Pharmacy is a specialty pharmacy that is focused exclusively on providing medications and support services to people living with HIV/AIDS. Visit

About Galea Life Sciences, Inc.

Galea Life Sciences, Inc. focuses on the emerging field of advanced nutritional supplements designed to support traditional medical treatments and therapies, and specializes in the formulation, manufacturing, marketing and distribution of innovative dietary supplements that benefit people undergoing medical treatments and therapies. Nutraplete is its introductory product.

Certain statements in this release constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast," "project," "intend," "expect," "should," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (finance or operating) or achievements to differ from future results, performance (financing and operating) or achievements expressed or implied by such forward-looking statements.

Statements herein express management's beliefs and expectations regarding future performance and are forward-looking and involve risks and uncertainties, including, but not limited to, the ability to negotiate outstanding prior debts of acquired companies; properly identify acquisition partners; adequately perform due diligence; manage and integrate acquired businesses; react to quarterly fluctuations in results; raise working capital and secure other financing; respond to competition and rapidly changing technology; deal with market and stock price fluctuations; and other risks.

Contact Information

  • For more information:
    Paul Zuromski
    Galea Life Sciences, Inc